Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of AdaptHealth Corp. (AHCO) and Encourages Long-Term Investors to Contact the Firm

AHCO

Philadelphia, Pennsylvania--(Newsfile Corp. - July 23, 2022) - Kaskela Law LLC announces that it is investigating AdaptHealth Corp. ("AdaptHealth" or the "Company") (NASDAQ: AHCO) on behalf of the Company's long-term investors.

Recently a securities fraud complaint was filed against AdaptHealth on behalf of certain investors who purchased shares of AdaptHealth's common stock between November 8, 2019 and July 16, 2021. According to complaint, during that time period AdaptHealth made a series of materially false and misleading statements to investors about the Company's business, operations, prospects, and leadership.

As detailed in the complaint, on April 13, 2021, AdaptHealth disclosed that it had put its Co-CEO "on unpaid leave" after claiming that it had "learned that authorities in Denmark have formally charged [him] with alleged tax fraud arising from certain past private activity." Following this news, AdaptHealth's stock price fell $7.30 per share, or nearly 20% in value.

Then, on July 19, 2021, before the market opened, Jehoshaphat Research published a report alleging that AdaptHealth's organic revenue growth had stalled, and had started to significantly decline. The report also reported that AdaptHealth had intentionally inflated and obscured its organic revenue growth figures in Q4 2020 and Q1 2021 by changing the calculation it used to derive the metric to include revenue growth attributable to recent acquisitions. Following the release of the Jehoshaphat Report, AdaptHealth's stock price fell an additional $1.51 per share, or nearly 6% in value.

The investigation seeks to determine whether the members of AdaptHealth's board of directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct.

Current AdaptHealth shareholders who purchased or acquired shares of the Company's common stock prior to January 1, 2020 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 299 - 0750, or by email (abell@kaskelalaw.com) or online at https://kaskelalaw.com/cases/adapthealth-corp/ , for additional information about this investigation and their legal rights and options.

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation, and has helped recover in excess of $100 million on behalf of victimized investors. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.

CONTACT:

KASKELA LAW LLC

D. Seamus Kaskela, Esq.
skaskela@kaskelalaw.com

Adrienne Bell, Esq.
abell@kaskelalaw.com

18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 - 1740
(484) 229 - 0750
www.kaskelalaw.com

This notice may constitute attorney advertising in certain jurisdictions.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/131742

Tags:


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today